Full history for every metric is available with a Kvantra account
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 7 | 8 | 51 | 267 | 364 | 692 | 1,054 | 1,361 |
| Operating profit | €m | -131 | 109 | ||||||
| Net profit | €m | -419 | -384 | -583 | -481 | -378 | -219 | 756 | 840 |
| EPS reported | € | -3.62 | 11.45 | ||||||
| Operating cashflow per share | € | 0.85 | 5.46 | ||||||
| Capex per share | € | 0.13 | 0.22 | ||||||
| FCF per share | € | 0.72 | 5.24 | ||||||
| Free cash flow | €m | 44 | 337 | ||||||
| Net debt | €m | 256 | -362 | ||||||
| Book value equity | €m | -163 | - | ||||||
| Book value per share | € | -2.69 | - | ||||||
| Number of shares | m | 60.61 | 68.32 | ||||||
| DPS (TTM paid) | € | 0.00 | 0.00 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | 19.70 | ||||||
| P/B LTM | x | -67.58 | 10.30 | ||||||
| P/S LTM | x | 15.90 | 14.61 | ||||||
| P/FCF LTM | x | 252.17 | 45.72 | ||||||
| EV/EBITDA LTM | x | -102.51 | 192.51 | ||||||
| EV/Sales LTM | x | 16.27 | 14.26 | ||||||
| Earnings Yield LTM | % | -1.99% | 5.08% | ||||||
| FCF Yield | % | 0.40% | 2.19% | ||||||
| Quality | |||||||||
| ROE | % | 134.58% | 190.44% | ||||||
| ROIC | % | -18.19% | 5.80% | ||||||
| Operating margin | % | -18.92% | 10.38% | ||||||
| Gross margin | % | 85.08% | 90.19% | ||||||
| FCF/Sales | % | 6.31% | 31.95% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +90.22% | +114.85% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.05 | 0.75 | ||||||
| Net Debt/EBITDA | x | -2.33 | -4.63 | ||||||
| EBIT/Net interest | x | -1.69 | 0.67 | ||||||
| Net debt/market cap | % | 2.32% | -2.35% | ||||||
| Net debt/Equity | x | -1.57 | - | ||||||
| Gross debt/equity | x | -5.35 | - | ||||||
ETFs that hold Ascendis Pharma
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| T. Rowe Capital Appreciation Equity ETF | TCAF | 9 | 2.35% |
| Morgan Stanley Pathway Funds - Small-Mid Cap Equity ETF | MSSM | 1 | 0.80% |
| ARS Focused Opportunity Strategy ETF | AFOS | 7 | 3.81% |
Funds with Ascendis Pharma among their ten largest holdings, largest fund first.
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| T. Rowe Capital Appreciation Equity ETF | TCAF | 9 | 2.35% |
| Morgan Stanley Pathway Funds - Small-Mid Cap Equity ETF | MSSM | 1 | 0.80% |
| ARS Focused Opportunity Strategy ETF | AFOS | 7 | 3.81% |
Funds with Ascendis Pharma among their ten largest holdings, largest fund first.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free